Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder), for oral inhalation useInitial U.S. Approval: 2013
Medication labelWhy this: Advisory · dailymed-prescription
BREO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). BREO ELLIPTA is indicated for the maintenance treatment of asthma in patients aged 5 years and older. BREO ELLIPTA is NOT indicated for the relief of acute bronchospasm.
- generic_name
- fluticasone furoate and vilanterol trifenatate
- product_names
- fluticasone furoate and vilanterol trifenatate
- ndc
- 0173-0916, 0173-0916-10, 0173-0859, 0173-0859-10, 0173-0859-14, 0173-0882, 0173-0882-10, 0173-0882-14
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en